Ambulero
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. They develop innovative treatments using stromal cells engineered to express E-selectin and gene therapy vectors to promote tissue repair and regeneration, aiming to treat vascular diseases and non-healing wounds.
Industries
Nr. of Employees
small (1-50)
Ambulero
1951 NW 7th Avenue, Ste. 600, Miami, Florida 33136
Products
AAV gene therapy candidate for rare vascular disease (E-selectin delivery)
A first-in-class adeno-associated virus (AAV) gene therapy approach designed to deliver and overexpress a cell adhesion molecule in diseased vascular tissues to promote regeneration and prevent limb/tissue loss.
AAV gene therapy candidate for critical limb ischemia (E-selectin delivery)
AAV-based gene therapy intended to overexpress a therapeutic adhesion molecule in ischemic tissues as a nonsurgical adjunct to improve perfusion and reduce amputation risk in critical limb ischemia.
Allogeneic MSC-based cell therapy engineered to express therapeutic transgene
An allogeneic mesenchymal stromal cell product transduced ex vivo to express a therapeutic adhesion molecule, developed to accelerate wound healing and tissue repair in ischemic and non-healing wounds.
AAV gene therapy candidate for rare vascular disease (E-selectin delivery)
A first-in-class adeno-associated virus (AAV) gene therapy approach designed to deliver and overexpress a cell adhesion molecule in diseased vascular tissues to promote regeneration and prevent limb/tissue loss.
AAV gene therapy candidate for critical limb ischemia (E-selectin delivery)
AAV-based gene therapy intended to overexpress a therapeutic adhesion molecule in ischemic tissues as a nonsurgical adjunct to improve perfusion and reduce amputation risk in critical limb ischemia.
Allogeneic MSC-based cell therapy engineered to express therapeutic transgene
An allogeneic mesenchymal stromal cell product transduced ex vivo to express a therapeutic adhesion molecule, developed to accelerate wound healing and tissue repair in ischemic and non-healing wounds.
Services
Engagement with academic and industry partners to co-develop gene and cell therapy programs and to support translational research.
Engagement with academic and industry partners to co-develop gene and cell therapy programs and to support translational research.
Expertise Areas
- AAV gene therapy development
- Mesenchymal stromal cell (MSC) engineering
- Preclinical vascular regeneration and wound-healing models
- IND preparation and regulatory strategy for rare diseases
Key Technologies
- AAV gene delivery
- Codon optimization and de novo vector synthesis
- Ex vivo viral transduction of MSCs
- Allogeneic mesenchymal stromal cell therapy
News & Updates
Groundbreaking findings published in the Annals of Surgery indicate that Ambulero’s gene therapy could salvage diseased limbs and eliminate the need for amputation.
The U.S. FDA announced the creation of a rare disease innovation hub to help advance new treatments, and Ambulero is interested in participating.
A CDC segment highlighted Ambulero’s efforts to develop therapies that may eliminate amputation for patients with Buerger’s Disease.
Ambulero is part of the 2023-2024 cohort, gaining mentorship and support to accelerate its development.
Tim Kelly, an industry leader in AAV technology, joins Ambulero’s SAB to support its gene therapy development.
Ambulero commits to submitting an IND for its lead gene therapy product, aiming to begin clinical trials.
Groundbreaking findings published in the Annals of Surgery indicate that Ambulero’s gene therapy could salvage diseased limbs and eliminate the need for amputation.
The U.S. FDA announced the creation of a rare disease innovation hub to help advance new treatments, and Ambulero is interested in participating.
A CDC segment highlighted Ambulero’s efforts to develop therapies that may eliminate amputation for patients with Buerger’s Disease.
Ambulero is part of the 2023-2024 cohort, gaining mentorship and support to accelerate its development.
Tim Kelly, an industry leader in AAV technology, joins Ambulero’s SAB to support its gene therapy development.
Ambulero commits to submitting an IND for its lead gene therapy product, aiming to begin clinical trials.